Cadrenal Therapeutics Files Definitive Proxy Statement
Ticker: CVKD · Form: DEF 14A · Filed: Jun 11, 2024 · CIK: 1937993
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
Related Tickers: CADX
TL;DR
CADX proxy filed for July 29 meeting - shareholders vote on company matters.
AI Summary
Cadrenal Therapeutics, Inc. filed its definitive proxy statement on June 11, 2024, for its annual meeting on July 29, 2024. The company, located at 822 A1A North, Suite 300, Ponte Vedra, FL 32082, is seeking shareholder approval for matters related to its corporate governance and operations. This filing is a standard procedural step for publicly traded companies.
Why It Matters
This filing outlines the agenda for Cadrenal Therapeutics' upcoming shareholder meeting, where key decisions about the company's future direction and governance will be made.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational distress.
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- June 11, 2024 (date) — Filing Date
- July 29, 2024 (date) — Meeting Date
- 822 A1A North, Suite 300, Ponte Vedra, FL 32082 (address) — Company Business Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When is the shareholder meeting for Cadrenal Therapeutics?
The shareholder meeting for Cadrenal Therapeutics is scheduled for July 29, 2024.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on June 11, 2024.
What is the company's primary business classification?
Cadrenal Therapeutics, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Where is Cadrenal Therapeutics, Inc. located?
Cadrenal Therapeutics, Inc. is located at 822 A1A North, Suite 300, Ponte Vedra, FL 32082.
Filing Stats: 4,257 words · 17 min read · ~14 pages · Grade level 14 · Accepted 2024-06-11 17:25:39
Key Financial Figures
- $0.001 — and outstanding common stock, par value $0.001 per share (“Common Stock”
Filing Documents
- ea0206592-04.htm (DEF 14A) — 1325KB
- tcadrenal_logo.jpg (GRAPHIC) — 46KB
- tcadrenal_logo1.jpg (GRAPHIC) — 46KB
- tproxy_001.jpg (GRAPHIC) — 1060KB
- tproxy_002.jpg (GRAPHIC) — 837KB
- 0001213900-24-051803.txt ( ) — 4067KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   50
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   55 TRANSACTIONS WITH RELATED PERSONS, PROMOTERS AND CERTAIN CONTROL PERSONS   57 NO DISSENTERS’ RIGHTS   59 ANNUAL REPORT ON FORM 10-K   59 NOTICE REGARDING DELIVERY OF STOCKHOLDER DOCUMENTS (“HOUSEHOLDING” INFORMATION)   59 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING   60 OTHER MATTERS   61 ANNEX A   A-1 ANNEX B   B-1 ANNEX C   C-1 i Table of Contents 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 PROXY STATEMENT SUMMARY This summary highlights information contained elsewhere in this proxy statement. It does not contain all of the information you should consider, and you should read the entire proxy statement carefully before voting. References in this proxy statement to the “Company,” “Cadrenal” “we,” “us,” and “our” refer to Cadrenal Therapeutics, Inc., a Delaware company. This proxy statement and form of proxy, together with the Company’s Annual Report on Form 10 -K for the year ended December 31, 2023, which is not a part of our proxy solicitation materials, are being distributed and made available to our stockholders on or about June 17, 2024. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082. Annual Meeting Information Date and Time:   July 29, 2024 at 10:00 a.m., Eastern Time Meeting Access:   Live Audio Webcast:  www.virtualshareholdermeeting.com / CVKD2024 Record Date:   June 6, 2024 Voting:    Stockholders have one vote per share on all matters presented at the annual meeting This year’s annual meeting will be a virtual meeting. You will be able to attend the annual meeting and vote your shares ele